Tyra Bioscience, Inc (TYRA)

Tyra Biosciences' stock (TYRA) has significantly increased, rising by 411.76% from April 4, 2025, to April 2, 2026. Key events include the release of earnings reports, such as the Fourth Quarter and Full-Year 2025 results, which highlighted the launch of the "dabogratinib 3x3" strategy. The company also presented clinical trial progress at conferences like the ASCO® Genitourinary Cancers Symposium and participated in investor conferences, including the Barclays Annual Global Healthcare Conference. Analyst coverage has been initiated with "Buy" and "Overweight" recommendations from firms like Canaccord Genuity and Barclays.

The demand for Tyra Biosciences' products and services is not subject to typical seasonal fluctuations. Demand is primarily driven by the progression of clinical trials, potential regulatory approvals, the prevalence of the diseases it aims to treat, and the medical community's adoption of new therapies upon commercialization.

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation precision medicines targeting fibroblast growth factor receptor (FGFR) biology for oncology and genetically defined conditions. Their proprietary SNÅP precision medicine platform facilitates rapid and precise drug design. Key product candidates include TYRA-300 (Dabogratinib), an FGFR3-selective inhibitor in clinical trials for metastatic urothelial carcinoma, non-muscle invasive bladder cancer, achondroplasia, and other FGFR3-driven genetic syndromes; TYRA-200, an FGFR1/2/3 inhibitor in Phase 1 for advanced/metastatic intrahepatic cholangiocarcinoma and other solid tumors; and TYRA-430, an FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, including hepatocellular carcinoma.

Tyra Biosciences, Inc. is headquartered in Carlsbad, California, United States, and primarily conducts its development of precision medicines for FGFR biology within the United States.

Tyra Biosciences has actively engaged with the scientific and investment communities through presentations at major conferences and participation in investor conferences, contributing positively to its brand reputation. These activities demonstrate ongoing research, clinical progress, and transparency. There is no information indicating any specific negative events that have significantly impacted Tyra Biosciences' reputation.

Tyra Biosciences, Inc. has a significant institutional ownership base, with 138 institutional owners and shareholders holding 49,296,776 shares as of April 8, 2026. Major institutional owners include Ra Capital Management, L.P., Alta Partners Management Company, L.P., and Commodore Capital Lp. Individual insider holdings also exist, with individuals like Nina S. Kjellson and Ronald V. Swanson holding shares.